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Abstract--Evidence is presented that oxygen products generated from xanthine oxidase (XO) may also be involved in the patho- 
genesis of neutrophil-mediate lung injury following intravascular activation of complement with cobra venom factor (CVF). CVF 
injection in rats resulted in a rapid increase in plasma of both XO activity (but not xanthine dehydrogenase) and its reaction prod- 
uct, uric acid. These changes were greatly attenuated in allopurinol-treated animals. The appearance of XO activity was paralleled 
by a rise in plasma of histamine. Prevention of histamine release by pretreatment of rats with cromolyn abolished both the rise in 
plasma histamine and the increase in XO activity. Since we have previously shown that histamine can enhance XO activity in vitro 
and in vivo (Am. J. Pathol. 135:203, 1989), these observations suggest that the increase in plasma XO activity following CVF in- 
jection is related to the appearance in plasma of histamine. Accordingly, pretreatment of rats with xanthine oxidase inhibitors (al- 
lopurinol, lodoxamide) or prevention of histamine release by pretreatment with cromolyn significantly attenuated development of 
lung injury following injection of CVF. Our data support the concept that oxygen radicals derived from both neutrophils and XO 
are playing a role in the CVF-induced acute lung injury. 
Keywords--Xanthine oxidase, Histamine, Oxygen radicals, Neutrophils, Complement, Lung injury, Rats, Free radicals 
INTRODUCTION 
Activation of  the complement  system in rats following 
intravascular injection of  cobra (Naja naja) venom fac- 
tor (CVF) leads to acute lung injury in which pulmonary 
capillary endothelial cells are the chief target of  injury. 
Development  of  the lung microvascular  injury is neutro- 
phil-dependent,  1 requires activation of C5, 2 and is ac- 
companied by the appearance in plasma and lung tissues 
of lipid peroxidation p roduc t s )  Both lung injury and 
lipid peroxide generation are significantly attenuated by 
pretreatment of  experimental  animals with catalase, hy- 
droxyl radical scavengers or iron chelators. 3 In vitro 
studies demonstrated that neutrophil-mediated killing of  
pulmonary artery endothelial cells is also largely pre- 
vented by catalase, iron chelators, or hydroxyl  radical 
scavengers 4 and that the target cells are the source of  
the iron requirement. 5 In an isolated perfused rat lung 
model,  similar data have been obtained. 6 These obser- 
vations suggest that activation of  blood neutrophils and 
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their generation of  an iron-catalyzed conversion product 
of  hydrogen peroxide,  most l ikely the hydroxyl radical,  
are directly responsible for injury of  lung vascular en- 
dothelial cells. 
Oxygen radicals may originate from different sources 
including enzyme systems of  mitochondria and endo- 
plasmic reticulum, the cyclooxygenase pathway, NADPH 
oxidase,  and xanthine oxidase. 7-1° While  the NADPH 
oxidase appears to be the major source of  oxygen radi- 
cals in cell and tissue injury during acute inflammatory 
reactions involving phagocytic cells, 11 xanthine oxidase 
appears to play an important role in experimental  isch- 
emia-reperfusion injuries.12-14 Following reoxygenation 
of  ischemic tissues, superoxide anion may be generated 
by the enzyme xanthine oxidase (XO) which is assumed 
to be activated during ischemia by a calcium-triggered 
limited proteolysis of  xanthine dehydrogenase (XD). 15 
In rat pulmonary artery endothelial cells (RPAEC),  con- 
version of  XD to XO has been observed following in 
vitro contact of  RPAEC with activated neutrophils 16 or 
exposure of  RPAEC to human recombinant C5a or tu- 
mor necrosis factor. 17 Furthermore,  recent observations 
suggest that physiologic concentrations of  histamine can 
enhance XO activity in vitro as well as in vivo. t8 
In vitro experiments involving the killing of  rat pul- 
monary artery endothelial  cells, as assessed by release 
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of 5~Cr, have indicated that both oxygen products from 
phorbol ester activated neutrophils as well as products 
of xanthine oxidase in endothelial cells are related to 
endothelial cell damage. 16 Furthermore, the product of 
XO appears to be 02- , s ince  preloading of endothelial 
cells with superoxide dismutase greatly attenuated their 
killing by activated neutrophils.19 
In order to determine if XO activity and histamine 
contribute to CVF-induced acute lung injury, we have 
examined CVF-treated rats for the appearance of XO 
activity and histamine in plasma and evaluated the ef- 
fects on CVF-induced pulmonary injury of interventional 
measures including XO inhibitors, histamine receptor an- 
tagonists, and the histamine release blocker, cromolyn. 
MATERIALS AND METHODS 
Animal model of lung injury 
As recently described,~ specific pathogen-free, adult 
(250-350 g), male Long Evans rats were used for the 
studies to be presented. Twenty units of cobra venom 
factor (CVF) per kg body weight were injected intrave- 
nously along with an aliquot of ~25I-bovine serum albu- 
min (125I-BSA). Animals were anesthetized with ketamine 
hydrochloride (100 mg/kg) (Parke Davis and Co., Mor- 
ris Plains, NJ) and exsanguinated 30 min later via the 
vena cava posterior. The lung vasculature was then per- 
fused through the right cardiac ventricle with l0 mL 
phosphate-buffered saline (pH 7.4). The lungs were re- 
moved and the amount of radioactivity remaining within 
the tissue assessed with a gamma counter. Lung damage 
was defined by the increased lung vascular permeabil- 
ity, as determined by the ratio of radioactivity present 
within total lung tissue and the amount of radioactivity 
present in 1.0 mL venous blood obtained when the ani- 
mals were killed. To test for the effects of XO inhibi- 
tors on CVF-induced lung injury, allopurinol (50 mg/kg 
body weight) and lodoxamide (5 mg/kg) (Upjohn Co., 
Kalamazoo, MI) were employed. Allopurinol was given 
intraperitoneally 20 min prior to CVF. Lodoxamide was 
injected intravenously 5 min before CFV treatment. 
Diphenhydramine (H1 antagonist) and cimetidine (H2 
antagonist) were dissolved in 1.0 mL saline and injected 
intraperitoneally (50 mg/kg) 5 min before CVF. Cro- 
molyn, dissolved in 1.0 mL saline, was injected intra- 
venously (20 mg/kg) 15 min prior to CVF. Protection 
from lung injury was determined by the following equa- 
tion: 
Protection (%) Test value - Saline value ] 
= 100 × [ 1 - Positive value - Saline valueJ 
Sample preparation and storage 
Blood samples were drawn from the posterior vena 
cava. The artificial conversion of xanthine dehydroge- 
nase to xanthine oxidase was minimized by rapid sample 
processing in the presence of dithiothreitol (DTT) and a 
protease inhibitor (phenylmethyl sulfonyl fluoride, PMSF). 
Blood samples were therefore collected into a process- 
ing and storage medium containing potassium phosphate 
(0.0024 M) - NaC1 (0.15 M) buffer, pH 7.35; DTT (10 
mM); PMSF (1 mM); and EDTA (10 mM). Samples 
were continuously processed such that no more than 2 h 
occurred between collection and analysis. Blood sam- 
ples for histamine analysis were collected in cold plas- 
tic tubes containing EDTA (10 mM) and then cooled 
immediately on ice. All samples were centrifuged at 4°C 
within 10 min following the sample collection. Follow- 
ing the recommendations of Lorenz et al, 2° only the up- 
per part of plasma was used for immediate histamine 
determination. 
Xanthine dehydrogenase/xanthine oxidase activity. 
Uric acid formation. 
XD and XO activities were assayed by measurement 
of uric acid formation at 293 nm in the presence or ab- 
sence of NAD ÷ at 37°C, as described by Waud and 
Rajagopalan. 21 The reaction mixture contained 100 ixL 
xanthine (50 IxM), 100 IxL NAD ÷ (500 IxM) or buffer 
in the absence of NAD ÷, 600 ~L potassium phosphate 
(0.0024 M) and sodium chloride (0.15 M) at pH 7.35, 
and 100 IxL rat plasma to a final plasma content of 5% 
(v/v). Furthermore, as indicated, the reaction mixture 
contained 100 IxL of the uricase inhibitor 2,4 dihydroxy- 
6-carboxy-l,3,5 triazine (oxonate) 22 (Aldrich Chemical 
Company Inc., Milwaukee, WI) present in a final con- 
centration of 3 ixM. XO and XD activities were ex- 
pressed as [nmol uric acid formed/ml of plasmaJmin]. 
Uric acid determination 
Plasma levels of uric acid were determined spectro- 
photometrically at 293 nm and expressed as [txM] using 
a molar extinction coefficient of 7.59 cm-XmM-x for 
uric acid. 23 Proof that uric acid was being measured 
was obtained by the addition of uricase. 
Histamine radioimmunoassay 
To determine plasma histamine we used a commer- 
cially available kit from Amak Inc. (Westbrook, ME). 
This assay is based on the acylation of plasma histamine 
and its competition with 125I-acylated histamine for 
binding to a mouse monoclonal antibody. Results were 
calculated employing a standard curve from seven stan- 
dard samples ranging between 0 and 150 nM. Results 
were expressed as [nM]. 
Xanthine oxidase and lung injury 
Table 1. Effect of various interventional measures on CVF-induced acute lung injury 
Number of Lung Injury* Significance Protection 
Treatment Animals (x ± SEM) (p value) (%) 
Saline 5 0.17 ± 0.02 
CVF (20 U/kg) 5 1.04 _ O. 11 
CVF plus 
Allopurinol (50 mg/kg) 4 0.49 --- 0 .04 <0.01"* 63 
Lodoxamide (5 mg/kg) 6 0.60 ___ 0.07 <0.01"* 51 
Cromolyn (20 mg/kg) 4 0.31 ___ 0.12 <0.01"* 84 
Diphenhydramine (50 mg/kg) 4 0.85 __. O. 14 NS** 22 
Cimetidine (50 mg/kg) 4 0.53 -± 0.12 <0.05** 59 




Unless otherwise stated, reagents were purchased 
from Sigma Chemical Corp. (St. Louis, MO) and were 
of the highest purity available. 
Statistical analysis 
Data in various groups were expressed as mean -+ 
standard error of the mean (SEM). For comparing of the 
response between two treatments a paired t test was 
used. To determine the significance of differences be- 
tween controls and multiple experimental groups two- 
way analysis of variance in combination with the Dunnetts 
multiple comparisons test was used. Statistical signifi- 
cance was defined as p < 0.05. Specifics regarding the 
number of experiments, and so forth, are contained in 
the text or within Table 1. 
RESULTS 
Increases in plasma xanthine oxidase activity following 
CVF injection 
Intravenous bolus injection into rats of cobra venom 
factor (CVF) resulted in a rapid increase in plasma XO 
activity (defined as in vitro production of uric acid in 
the presence of oxonate) for the first 10 min post CVF 
application, followed by a fall in the levels of plasma 
XO (Fig. 1). This increase in enzyme activity was re- 
stricted to XO activity; no rise in xanthine dehydroge- 
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Fig. 1. Rat plasma levels of xanthine oxidase and xanthine dehydrogenase following systemic complement activation by intravenous injection of 
cobra venom factor (CVF; 20 U/kg). *p<0.01 compared to time-zero value; NS: not significant; four to six animals were examined at each time 
point. 
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Fig. 2. Appearance of uric acid in plasma of rats injected with cobra venom factor (CVF; 20 U/kg). Maximal increases of uric acid were seen 
when rats were pretreated with the uricase inhibitor, oxonate (50 mg/kg; i.p.), which prevents the conversion of uric acid to allantoin. Pretreat- 
ment with the xanthine oxidase inhibitor, allopurinol (50 mg/kg; i.p.) significantly reduced plasma levels of uric acid. *p<0.01 compared to time- 
zero value; **p<0.05 compared to 15-rain value (CVF+oxonate); NS: not significant; each data point represents the mean obtained from three to 
five animals. 
order to demonstrate if uric acid production occurs in 
vivo following CVF injection, animals were pretreated 
with oxonate (50 mg/kg; i.p.) in order to prevent 
uricase-mediated breakdown of uric acid to allantoin. 
The rise in plasma XO activity (Fig. 1) was accompa- 
nied by a significant increase in plasma levels of uric 
acid peaking 15 min after CVF injection (Fig. 2). Pre- 
treatment of CVF-injected rats with allopurinol (together 
with oxonate) significantly diminished the plasma levels 
of uric acid (Fig. 2). These observations suggest that 
systemic complement activation following CVF injec- 
tion results in both increased plasma levels of XO activ- 
ity and its reaction product uric acid (and, consequently, 
superoxide and hydrogen peroxide). 
CVF-induced increases in plasma histamine levels and 
their effect on xanthine oxidase activity 
Recently, we have shown in vitro that histamine can 
enhance the catalytic activity of XO (but not XD) and 
have demonstrated in vivo that acute dermal microvas- 
cular injury (edema) in rats following thermal trauma is 
mediated by oxygen radicals generated by histamine- 
enhanced XO. 18 In order to examine if a similar mech- 
anism of histamine-dependent augmentation of XO may 
play a role in CVF-induced acute lung injury, plasma 
histamine levels were determined and the effect of cro- 
molyn treatment on the activity of plasma XO follow- 
ing CVF injection was examined. As shown in Fig. 3A, 
intravenous injection of CVF in rats caused a rapid in- 
crease in plasma histamine levels, peaking at 10 min 
post CVF, essentially paralleling the changes in plasma 
of XO activity (Fig. 3B). Treatment of experimental an- 
imals with the membrane stabilizer, cromolyn, com- 
pletely prevented the appearance of histamine in plasma 
of CVF-treated rats (Fig. 3A). Furthermore, the sup- 
pression of histamine release by cromolyn also com- 
pletely prevented the increase in plasma of XO activity 
(Fig. 3B). The addition in vitro of histamine (1 IxM) to 
plasma obtained 15 min after CVF injection into rats 
that were pretreated with cromolyn caused an increase 
in XO activity from 5.7 -+- 0.23 nmol/ml/min (n=3)  to 
17.03 _+ 0.44 nmol/ml/min (n = 3) similar to that shown 
in Fig. 3B. These observations suggest that histamine 
being released in the course of CVF-induced systemic 
complement activation is playing a crucial role in mod- 
ulating the catalytic activity of plasma XO activity. 
Protection from acute lung injury 
In the model of acute lung injury accompanying sys- 
temic activation of complement induced by infusion of 
CVF, the resulting injury is known to be related to the 
generation of H20 2 by activated neutrophils and demon- 
strates a requirement for iron, suggesting a possible role 
for "OH.  24 If XO-derived oxygen radicals play a role as 
well, both treatment of experimental animals with in- 
hibitors of XO or the prevention of histamine release by 
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Fig. 3. Concomitant appearance of histamine (Frame A) and xanthine oxidase activity (Frame B) in plasma of rats injected with cobra venom fac- 
tor (CVF; 20 U/kg). Pretreatment of experimental animals with cromolyn (20 mg/kg; i.v.) prevented release of histamine (Frame A) thus resulting 
in loss of histamine-mediated enhancement of plasma xanthine oxidase activity (Frame B). Histamine and XO activity were measured in the same 
animal. *p<0.01 compared to time-zero value; NS: not significant; four to six animals were used at each time point and treatment. 
cromolyn (see above) should attenuate acute pulmonary 
injury in the rat following CVF injection. Accordingly, 
the experiments as shown in Table 1 were accomplished. 
Intravenous injection of  CVF into rats produced a six- 
fold increase in lung vascular permeability (to 1.04 --- 
0.11) as compared to saline-infused animals (0.17 ___ 
0.02). Pretreatment of  animals with the XO inhibitors, 
lodoxamide 25 or allopurinol, resulted in a 51% and 63% 
reduction in CVF-induced lung injury, respectively (p 
< 0.01). A striking attenuation of  acute lung injury was 
also observed when animals were treated with cromolyn 
(Table 1). These observations support the concept that 
histamine may play a significant role in complement- 
dependent and oxygen radical-mediated acute lung in- 
jury by enhancing plasma XO activity in vivo. 
Surprisingly, the histamine H2 receptor antagonist, 
cimetidine, also attentuated the lung injury, whereas the 
H1 receptor antagonist, diphenhydramine, had no sig- 
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nificant effect (Table 1). Whether stimulation of H2 re- 
ceptors plays a role in CVF-induced pulmonary injury 
remains unclear. However, the protective effect of ci- 
metidine may as well be explained by its known ability 
to effectively scavenge hydroxyl radicals, whereas 
diphenhydramine possesses little scavenging capacity. ~8 
DISCUSSION 
In earlier studies, we demonstrated that systemic 
complement activation by cobra venom factor (CVF) re- 
sults in acute lung microvascular injury and that this in- 
jury depends on the availability of neutrophils and their 
production of toxic oxygen metabolites. 1'23 This was 
supported by the observation that neutrophil depletion 
of experimental animals prior to intravascular comple- 
ment activation or pretreatment with antioxidant en- 
zymes, iron chelators, or hydroxyl radical scavengers 
resulted in significant protection from pulmonary injury. 
Morphologic studies have revealed damage of lung al- 
veolar capillary endothelial cells in areas of intimate 
contact with neutrophils and, adjacent to these areas, 
destruction of vascular basement membrane, fibrin de- 
position, interstitial and intraalveolar edema, and 
intraalveolar hemorrhage. The trigger for this event is 
intravascular complement activation and generation of 
C5a 2 which causes activation and sequestration of blood 
neutrophils in the lung vasculature and their release of 
oxygen radicals. Endothelial cell-derived oxidants may 
augment this event, z6 Because interventional measures 
using antioxidant enzymes, iron chelators, or hydroxyl 
radical scavengers consistently provided higher levels of 
protection than did neutrophil depletion, 1,23 additional 
source(s) of toxic oxygen metabolites had to be consid- 
ered. The present observations point at xanthine oxidase 
(XO) as being the additional source of oxygen radicals 
involved in the pathogenesis of acute lung injury fol- 
lowing systemic complement activation. 
The data obtained in the present study demonstrate 
that, when intravascular activation of complement oc- 
curs, the resulting acute lung injury can be attenuated 
by XO inhibitors, suggesting involvement of XO-gener- 
ated oxygen radicals in the tissue injury. In addition, 
there is evidence of increased plasma levels of both XO 
and uric acid following CVF-induced complement acti- 
vation. This increase is significantly attenuated by ad- 
ministration of the XO inhibitor, allopurinol, as dem- 
onstrated in the experimental animals. Since neutrophil 
depletion, XO inhibitors, and antioxidants are protec- 
tive, it can be assumed that both neutrophil and XO-de- 
rived oxygen radicals are playing a role in the CVF- 
induced acute lung injury. 
As indicated above, this pattern is consistent with 
what we now believe to be the mechanism by which 
activated neutrophils kill rat pulmonary artery endothe- 
lial cells. Presumably, H20 2 production by the neutro- 
phils and 0 2- generation by endothelial cells (via XO) 
results either in formation of .OH via an iron-dependent 
pathway, or H20 2 could conceivably cause nitric oxide 
(NO.) generation in the endothelial cells, resulting in an 
interaction of NO. with 0 2 - to generate .OH via an 
iron-independent pathway. 27 
The rise in plasma XO activity was found to be par- 
alleled by significant increases in plasma histamine lev- 
els. Prevention of histamine release by pretreatment of 
CVF-injected rats with cromolyn also prevented the in- 
crease in plasma XO activity and significantly attenu- 
ated the oxidant-mediated lung injury. This is in accor- 
dance with recent studies from our laboratory which 
provided evidence to suggest that histamine plays a cru- 
cial role in the modulation of XO activity following 
thermal injury of rat skin. In this model, increased lev- 
els of XO activity appear in plasma and oxidants de- 
rived from XO have been shown to be largely responsible 
for the microvascular injury (edema formation) in the 
burned skin. Friedl et al. ~8 have observed in vitro that 
histamine and its metabolic derivatives increase the cat- 
alytic activity of XO (but not XD) in rat plasma and rat 
pulmonary artery endothelial cells. Histamine also en- 
hanced the activity of purified XO obtained from human 
milk. Following thermal injury of rats, it was then ob- 
served that the increase in plasma XO was paralleled by 
a significant rise in plasma histamine levels, whereas 
the plasma XD levels remained completely 
unchanged. 18 As in the CVF lung injury model, the rise 
in both plasma histamine and XO activity could be pre- 
vented by cromolyn pretreatment of the thermally in- 
jured rats. These interventional measures also attenuated 
the development of thermal skin edema. 18 Taken to- 
gether, these observations suggest that the enhancement 
by histamine of the catalytic activity of XO may be of 
general importance in the pathogenesis of inflammatory 
reactions. The mechanism by which histamine can en- 
hance the catalytic activity of XO is not yet known. 
Following systemic complement activation in rats, 
plasma levels of XO activity and concomitant uric acid 
production reach peak values within 10 to 15 min of 
CVF injection. Full development of oxidant-mediated 
acute lung injury can be observed within 20 to 30 min 
post CVF. Although some of the oxygen radicals are 
being released from activated blood neutrophils seques- 
tered in the lung microvasculature, our data support the 
concept that toxic oxygen species derived from plasma 
XO are also participating in the lung microvascular in- 
jury. This hypothesis of endothelial cell injury being 
brought about by oxidants derived from circulating XO 
is supported by recent reports in the literature. Parks et 
al. 28 reported that intraarterial infusion of XO into 
nonischemic intestines produced an increase in 
microvascular injury that was comparable to that ob- 
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served after ischemia/reperfusion and was significantly 
attenuated by antioxidant interventions. Accordingly, 
XO activity (in amounts that were released into the 
perfusate of ischemic livers), when supplied with sub- 
strate, was shown to produce severe vascular endothe- 
lial injury in vitro, even in the presence of serum or 
whole blood. 29 
Generation of C5a following systemic complement 
activation has been shown to be essential for the de- 
velopment of lung microvascular injury after CVF in- 
jection. 2 In this model, C5a appears to be important 
for both the massive accumulation of blood neutrophils 
in the lung vasculature and the liberation of histamine 
from mast cells and basophils. As mentioned above, 
histamine plays an important role because of its ability 
to significantly enhance XO activity and thus directly 
affect oxidant production by this enzyme. Prevention 
of histamine release by cromolyn completely prevented 
the increase in plasma XO activity and reduced lung 
injury by 84%. The observation that cromolyn is more 
protective than the XO inhibitors (51-63% protection) 
is somewhat surprising but may be explained, in part, 
by its mildly inhibitory effect on neutrophil accumu- 
lation. 3° There is also the possibility that histamine per 
se may cause some increase in lung microvascular per- 
meability following systemic complement activation. 
This would explain why the H1 antagonist, diphenhy- 
dramine, exhibited a 20% (although nonsignficant) re- 
duction in lung injury as determined by the 
extravasation of t25I-BSA. The lung protective effect 
(59%) of the H2 antagonist, cimetidine, may be ex- 
plained by the fact that it is an effective scavenger of 
hydroxyl radical. 18 
The protective effects of allopurinol and lodoxamide 
have to be viewed with some caution since these XO 
inhibitors have also been found to scavenge hydroxyl 
radical. 18'31 Since hydroxyl radical has been identified 
as the most likely oxidant involved in CVF-induced lung 
injury, 24 and because of the fact that rather high doses 
of allopurinol had to be used in vivo (up to 50 mg/kg 
body weight), it seems possible that protection from 
CVF lung injury by allopurinol is at least partially re- 
lated to scavenging of hydroxyl radical. However, it can 
be calculated that the likely plasma level of lodoxam- 
ide, which (at 5 mg/kg) was similar protective, is in the 
low wM-range, too low to allow for significant .OH 
scavenging. Because the generation of superoxide an- 
ion, hydrogen peroxide, and uric acid is the result of 
the action of XO on its substrates, hypoxanthine and 
xanthine, the inhibitory effects of the XO inhibitors on 
uric acid production and lung tissue injury further sup- 
port our assumption that the CVF-induced lung mi- 
crovascular injury is, at least in part, being mediated by 
XO-generated oxygen radicals. 
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ABBREVIATIONS 
C V F - - c o b r a  v e n o m  fac tor  
X D - - x a n t h i n e  d e h y d r o g e n a s e  
X O - - x a n t h i n e  ox idase  
